Chaperon-like Activation of Serum-Inducible Tryptophanyl-tRNA Synthetase Phosphorylation through Refolding as a Tool for Analysis of Clinical Samples  by Paley, Elena L.
Chaperon-like Activation
of Serum-Inducible
Tryptophanyl-tRNA Synthetase
Phosphorylation through
Refolding as a Tool for Analysis
of Clinical Samples1
Elena L. Paley*,†
*College of Allied Health and Nursing, Nova Southeastern
University, Kendall Campus, Miami, FL, USA; †Expert
BioMed, Inc, Miami, FL, USA
Abstract
Tryptophanyl-tRNA synthetase (TrpRS) expression alters in colorectal (CRC), pancreatic (PC), and cervical (CC) cancers.
Here, phosphorylation of unfolded TrpRS and its fragments is stimulated by human cancer sera (CS; n= 13) and serum
of rabbit tumor induced by Rous sarcoma virus, unaffected by donor sera (NS; 11/15) and abolished by alkaline phos-
phatase. At 20 years of follow-up, serum-inducible TrpRS phosphorylation found years before healthy donors (3/15)
diagnosed with PC, CRC, or leukemia. I have examined a specificity of serum-inducible TrpRS phosphorylation
and found, surprisingly, that serine phosphorylation of unfolded TrpRS is stimulated by anti-TrpRS rabbit antisera
but is unaffected by rabbit nonimmune sera and antisera to other antigens. Anti-TrpRS immunoglobulin G (IgG)
inhibits phosphorylation of full-length TrpRS and stimulates phosphorylation of its 20-kDa fragment. Phosphorylation
of this fragment is stimulated also by CS but not NS. 2-Mercaptoethanol and cyclic AMP exerted synergistic inhibi-
tory effect on TrpRS phosphorylation. Anti-TrpRS sera and casein act as chaperones increasing TrpRS phosphorylation
through refolding. Histone-specific protein kinase activity in CS (n = 44) and anti-TrpRS sera was lower than that in NS
(n=11), rabbit nonimmune sera and antisera to other antigens. TrpRS inhibitors, tryptamine, and tryptophanol stimulate
in vivo accumulation of enzymatically inactive, nonphosphorylated, aggregated and anti-TrpRS IgG refoldable TrpRS.
Phosphorylation of postsurgical tissues (n = 18) reveals TrpRS in ovarian cancer (OVC) and CC but not in normal pla-
centa and liver. In OVC, TrpRS phosphorylation increase correlates with elevated tryptophan-dependent ATP–inorganic
pyrophosphate exchange. Although not inducing cancer, TrpRS triggers signaling concomitant with cancer.
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Introduction
Some malignancies, notably lung cancer and pancreatic cancer (PC),
are mostly detected only in late stages. Screening tests of bodily fluids
are a way of detecting cancer early, before there are any symptoms.
Tryptophanyl-tRNA synthetase (TrpRS) catalyzing attachment of its
substrate, tryptophan, to cognate tRNAtrp in protein biosynthesis is
suggested to be a prognostic marker in cancer tissues [1–4]. TrpRS be-
longs to a family of aminoacyl-tRNA synthetases (ARS). The first step
in ARS activity is amino acid activation with formation of aminoacyl-
adenylate and release of inorganic pyrophosphate (ATP-PPi exchange),
and the second step is formation of aminoacyl-tRNA. In colorectal
cancer (CRC), changes in TrpRS expression correlate with survival: a
low protein expression in human tissues correlated with a worse cancer
prognosis (increased risk for recurrence and worse survival) than a
higher human TrpRS (hTrpRS) expression [1]. In human pancreatic
cancer (PC) cells, high messenger RNA (mRNA) and protein TrpRS
expression correlates with higher growth rate and metastatic ability,
whereas hypoxic state associates with reduced hTrpRS expression. In-
versely, the alternatively spliced antiangiogenic TrpRS-truncated form
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is upregulated by hypoxia. Therefore, alternatively spliced TrpRS forms
are differentially regulated by hypoxia in PC cells [3]. Tumor hypoxia is
associated with higher metastatic ability and worse prognosis. TrpRS is
identified as a marker in cervical cancer (CC) that originates from human
papillomavirus infection and progresses through histologically defined
premalignant stages. TrpRS protein expression has been compared in
normal cervical epithelium and patient-matched high-grade squamous
intraepithelial lesions (HSIL) with cervical carcinoma tissue from the
same patient population [2]. An increase in TrpRS expression (1.7-fold)
was found in cervical carcinoma compared with that in normal tissue.
TrpRS expression was decreased (1.4-fold) in HSIL compared with that
in normal and was upregulated (2.4-fold) in cancer compared with that
in HSIL [2]. TrpRS protein is upregulated (2.7 times) in clear cell
adenocarcinoma, with a highly malignant potential in human epithelial
ovarian cancer (OVC) when compared with mucinous ovarian adeno-
carcinoma of low malignant potential [4]. TrpRS gene expression is
upregulated 5.7-fold by ovarian hormone estrogen [5], which is able to
promote cell proliferation in the breast and the uterus.
TrpRS is an interferon-inducible protein upregulated in hosts after
some viral infections. TrpRS gene expression is induced in the liver dur-
ing hepatitis B viral clearance [6] and upregulated (1.65-fold) by the K15
protein of Kaposi sarcoma–associated herpesvirus [7]. Notably, TrpRS
mRNA expression is upregulated 800-fold at 8 hours after infection
with human cytomegalovirus [8], a frequent opportunistic infection in
immunocompromised individuals particularly those receiving organ
transplants and harboring human immunodeficiency virus infection.
tRNAtrp used to prime reverse transcription in Rous sarcoma retro-
virus (RSV). TrpRS is present in RSV at approximately 12 molecules/
virion, but the determined number of avian TrpRS molecules in RSV
may be an underestimate [9]. The product of RSV is a transforming
phosphoprotein pp60 src. Recent studies have shown that c-src, a non-
receptor tyrosine kinase, exhibits elevated protein levels and activity
in numerous types of human cancers [10]. Furthermore, it has been
found to be a critical component of multiple signaling pathways that
regulate proliferation, survival, metastasis, and angiogenesis [11]. The
role of retrovirus-specific packaging of TrpRS is not known.
Bovine TrpRS (bTrpRS) is a serine/threonine phosphoprotein. The
60-kDa bTrpRS and its 40-kDa proteolytic forms exhibit similar
phosphopeptides [12]. Protein kinase (PK) associated with bTrpRS
(TrpRS-PK) phosphorylates nuclear protein histones, preferably his-
tone H2B [12]. TrpRS-PK, with molecular mass ∼60 kDa (under
denaturing conditions), is copurified and coimmunoprecipitated with
TrpRS. Protein phosphorylation is one of the most significant signal
transduction mechanisms by which intercellular signals regulate crucial
intracellular processes such as ion transport, cellular proliferation, and
hormone responses [13]. Consistent with the complex role of this post-
translational modification in the cell, phosphorylation can be regulated
by activators or inhibitors and phosphorylation can be regulated by
other proteins or by themselves (autophosphorylation). TrpRS binds
to its substrate, tryptophan, whereas increase in plasma-free tryptophan
concentrations is a common feature of both human solid and hemato-
logic malignancies and some experimental tumors [14–18]. Amino
acids stimulate ribosomal protein S6 phosphorylation [19]. TrpRS
in vivo phosphorylation is modulated in bovine kidney (MDBK)
cells [20] and human CC (HeLa) cells [21] by tryptophan analog,
tryptamine—a TrpRS competitive inhibitor. Tryptamine is a metabolic
product of tryptophan decarboxylation by aromatic L-amino acids de-
carboxylase. Abnormally aggregated TrpRS was found in tryptamine-
treated cells and in a brain of a patient with Alzheimer disease (AD)
[22–24]. Anti-TrpRS monoclonal antibody is able to disaggregate the
self-assembled fibrils of TrpRS-derived NH2 peptide [23]. TrpRS pro-
tein expression but not mRNA expression is downregulated by wild-
type p53, a tumor suppressor, suggesting binding of p53 and TrpRS
[25]. The p53 accumulates in response to cellular stress, e.g., DNA
damage, oncogene activation, and hypoxia. TrpRS is tightly associated
with DNA polymerase α [26]. Heme, a porphyrin coordinated with
Fe, binds hTrpRS and regulates its tRNA aminoacylation activity
[27]. Porphyrins have been increased in the blood of individuals with
different tumor types [28]. The specific function of TrpRS phosphory-
lation has not yet been identified. For some other ARS, phosphoryla-
tion may affect the enzymatic activity [29]. In this study, TrpRS and
histones were used as exogenous substrates to explore serum-inducible
phosphorylation in a human cohort and in rabbits including rabbit
bearing tumor induced by RSV (TBR). TrpRS as an endogenous sub-
strate in the phosphorylation of human normal tissues and malignant
and nonmalignant gynecologic tumors was also studied.
Materials and Methods
Human Tissue and Serum Samples
Postsurgical tissues were provided by Dr Nikolai E. Zinov’ev, MD
(N. N. Blokhin Russian Cancer Research Center, Moscow, Russia).
Human blood samples were provided by Dr Regina R. B. Paley, MD
(City Hospital 15, Tashkent, Uzbekistan), or were obtained from
National Oncological Scientific Center, Tashkent, Uzbekistan, and
volunteers. Ethical approval (no. 00-001) was obtained from the ethics
committee at Expert BioMed, Inc (Miami, FL).
Purification of bTrpRS
bTrpRS was purified from bovine pancreas using two different
protocols (A and B) as described previously [12]. Purified bTrpRS was
stored (−80°C) in 0.5 mM dithiothreitol (DTT; Sigma, St Louis, MO),
0.1 mM tryptophan, 0.1 mM EDTA, 10 mM Tris-HCl, pH 7.5, and
0.7mMdi-isopropyl fluorophosphate (DFP) or under 60% ammonium
sulfate (Merck,Whitehouse Station, NJ). TrpRS precipitated by ammo-
nium sulfate precipitation TrpRS was dialyzed (3.5 hours) before use
against distillated water (90 minutes) and water changed (2 hours) or
dialyzed (48 hours) against water (24 hours) and finally against 10 mM
Tris-HCl, pH 7.2 (24 hours at 4°C).
Rabbit Antisera, Immunoglobulin G, and Monospecific
Polyclonal Antibodies Specific to TrpRS
Rabbits (Chinchilla sp) were immunized by four subcutaneous injec-
tions with bTrpRS purified using protocol A (5mg/animal) in Freund ad-
juvant (Difco, Franklin Lakes, NJ) with intervals of 21 days, 26 days, and
9 months. Blood was collected on the eighth day after the last injection.
To isolate the anti-TrpRS immunoglobulin G (IgG) fraction, 20 ml
of borate buffer (0.15 M NaCl, 0.2 M boric acid, pH 8) was added to
anti-TrpRS rabbit serum (20 ml). Then, 2.53 M Na2SO4 (40 ml) was
added for precipitation (1 hour). After centrifugation, pellets were
dissolved in 0.15 M NaCl and an equal volume of 2.53 M Na2SO4
was added (1 hour, room temperature). After centrifugation, the pellet
was resuspended in 0.15 M NaCl (40 ml) and dialyzed against water
(1 L for 1 hour), then against 0.15 M NaCl (2 L for 2 hours), and
against 0.15 M NaCl (2 L overnight at 4°C); two more changes
(1 L each) with 0.1 M sodium phosphate buffer and 0.15 M NaCl,
pH 7 (phosphate-buffered saline [PBS]) overnight (4°C), were made.
After dialysis, the anti-TrpRS IgG fraction was further purified on
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diethylaminoethyl (DEAE) 52-cellulose (column of 9-cm height ×
2.2-cm diameter) prewashed with PBS and was eluted (40 ml at
4°C). The protein concentration was 1 mg/ml. To obtain monospecific
polyclonal antibodies, 1% aminocellulose was used (kindly provided
by Dr R.S. Nezlin). To convert aminocellulose into diazocellulose,
hydrochloric acid (0.33 ml of undiluted HCl) was added to amino-
cellulose (2ml) and thenNaNO2 (45mg) was added (in ice for 35min-
utes). The diazocellulose was washed with borate buffer (60 ml at
4°C) and then incubated with 200 μl of TrpRS (10 mg/ml) in borate
buffer (1 ml) overnight at 4°C. The TrpRS-diazocellulose was washed
three times with borate buffer and was resuspended in the same buffer
(2 ml) with sodium azide (0.02%). The IgG fraction eluted from
DEAE 52-cellulose (20 ml) was incubated with TrpRS immobilized
on diazocellulose (300 μl; 1.6 mg of TrpRS/ml of diazocellulose) over-
night at 4°C. After centrifugation, TrpRS-diazocellulose was washed
six times with 0.01 M sodium phosphate buffer and 0.15 M NaCl
(100 ml), eluted with 0.2 M glycine-HCl pH 2.5 (350 μl for 15 min-
utes), neutralized with supernatant (monospecific antibodies; 5 M
NaOH), and stored with sodium azide (0.02%). The antibody used
here is specific for cytoplasmic TrpRS.
Casein
Total casein was isolated from cow’s milk as described [30] and
lyophilized (provided by Dr Y.Y. Kit). Casein (10 mg/ml in 0.1 M
Tris-HCl pH 8.7 or water) was preboiled for 25 or 5 minutes to in-
activate possible PK activity before use. Molecular weights of casein
forms are from 23.6 (αs-casein) to ∼34 kDa.
Histones
Total histones were isolated from the nuclei of Wistar rat thymus by
acid extraction with 0.4MH2SO4 or HClO4 followed by neutralization,
dialysis, and purification by chromatography on Amberlite CG-50.
Lyophilized histones were kindly provided by Dr Y. S. Mangutova.
The histones included subclasses H1/H5 (linker histones) and histone
core containing H2A and H2B (doublet), H3 and H4.
Rabbit Polyclonal Antisera Specific for α-Fetoprotein or
Thomsen-Friedenreich Antigen
Lyophilized rabbit monospecific antiserum to α-fetoprotein (AFP)
was dissolved in water (1 ml). Polyclonal rabbit anti–human AFP is
from the diagnostic kit (produced by N.F. Gamaleya Institute for
Epidemiology and Microbiology, Moscow, Russia). Affinity-purified
AFP from the serum of a patient with hepatocellular carcinoma was used
as antigen. Polyclonal rabbit undiluted antiserum against carcinoma-
associated Thomsen-Friedenreich (TF) antigen from human breast
tissue [31] was provided by Elnora Daminowa (National Oncological
Scientific Center, Tashkent, Uzbekistan). Rabbits were immunized twice
in lymph nodes by TF.
Multienzyme ARS Complex
Some phosphorylation experiments were conducted with multi-
enzyme complex from rabbit liver (fraction A) containing seven ARS
isolated as described [32] and provided by Drs Alexey Wolfson and
Valery Filonenko.
Immunoprecipitation of bTrpRS by TBR Serum Followed by
Immune Complex PK Activity Testing
Purified bTrpRS (20 μg/sample) was preincubated with nonimmune
rabbit serum (2 μl) in PBS (100 μl for 1 hour at 37°C). Then, 10%
protein A–Staphylococcus aureus in 0.15 M NaCl, 0.01 M sodium phos-
phate pH 7.2, 1% NP-40 (Sigma), 1% sodium deoxycholate (Sigma),
0.5% SDS, and 3 mM phenylmethylsulfonyl fluoride (PMSF; RIPA
buffer) were added (20 μl) for 20 minutes at 37°C. Supernatants were in-
cubated with 2 μl of either nonimmune rabbit sera or TBR serum (kindly
provided by Dr N. Mazurenko [10]) overnight at 4°C and then with
10% S. aureus (13 μl/probe) for 30 minutes at 37°C. Pellets were washed
three times with RIPA buffer (1 ml), once with 10 mM Tris-HCl,
pH 7.2, 3 mM PMSF (1 ml), once in 1 ml of 20 mM Tris-HCl
(Calbiochem, Basel, Switzerland), pH 7.2, 2 mM MnCl2 (Fluka,
La Jolla, CA), 5 mMMgCl2, 1 mM5′AMP, 50mM2-mercaptoethanol
(2-ME), 50 μM EDTA, and 3 mM PMSF (PK buffer). Pellets were
incubated in PK buffer with the addition of [γ-32P]ATP (1.5 μl/probe,
2000 Ci/mmol, 500 μCi/0.05 ml of water; Institute of Nuclear Physics,
Uzbekistan) for 15 minutes at 37°C. PK reaction was terminated by
Laemmli sample buffer (4 μl) by boiling for 5 minutes. Supernatants were
analyzed on 12.5% SDS–polyacrylamide gel electrophoresis (PAGE).
Protein markers used for SDS-PAGE (14-94 kDa; Pharmacia, Uppsala,
Sweden) were as follows: phosphorylase B (94 kDa), albumin (67 kDa),
ovalbumin (43 kDa), carbonic anhydrase (30 kDa), trypsin inhibitor
(20.1 kDa), and α-lactalbumin (14.4 kDa). Gel was stained with
Coomassie blue and dried, and autoradiography was obtained.
Tissue Extracts and Immunoblot Analysis
Tissue specimens were cut with scissors in the lysis buffer (0.25 M
sucrose [Merck], 0.01 M Tris-HCl pH 7.5, 1 mM DFP at 0°C or
in 50 mM Tris-HCl pH 7.5, 50 mM KCl, 1.5 mM EDTA, 10 mM
MgCl2, 1 mM DTT, 10% glycerol, and 3 mM DFP) and homoge-
nized in glass/glass homogenizer with a tight-fitting pestle. Mito-
chondrial fractions were obtained by differential centrifugation. The
extracts were spun at 600g at 2°C; the supernatant was spun at
12,000g at 2°C. The postmitochondrial supernatant was kept frozen
at −80°C until use or was used after preparation. To remove cyto-
plasm from the samples, mitochondrial pellets were incubated with
1.5 mg/ml digitonin (Merck), spun, and washed with lysis buffer.
The mitochondrial fraction was frozen in liquid nitrogen to grind
with porcelain pestle and then in glass/glass homogenizer with a
tight-fitting pestle in the lysis buffer. The lysates were spun (10,000g
for 15 minutes), and the supernatant was used for the analysis of
mitochondrial fraction.
The postmitochondrial and mitochondrial fractions were analyzed
by SDS-PAGE electrophoresis and then transferred onto two nitro-
cellulose membranes (0.45 μm; Schleicher & Schuell, Dassel, Germany).
The membrane was stained with Coomassie blue and washed with 5%
acetic acid or blocked in 0.1 M sodium phosphate pH 7.5, 0.15 M
NaCl, and 0.05% Twin-20 and then incubated with anti-TrpRS rabbit
monospecific antibodies (overnight at room temperature). After wash-
ing, the membrane was incubated with goat antirabbit Fab fragments
conjugated with horseradish peroxidase (Sigma) for 2 hours at room tem-
perature and washed with buffer (50 mM Tris-HCl pH 7.5, 0.15 M
NaCl). The reaction was developed with 0.05% 4-Cl-1-naphthol in
50 mMTris-HCl, pH 7.5, and 0.05% hydrogen peroxide. Alternatively,
after 12.5% SDS-PAGE of postmitochondrial extracts, the membrane
was blocked by 5% bovine serum albumin (BSA; Sigma), 0.15 M
NaCl, 10 mM Tris-HCl, pH 7.5, at 4°C overnight; incubated with
anti-TrpRS IgG for 90 minutes, washed by 1% BSA, 0.15 M NaCl,
10 mM Tris-HCl pH 7.5, overnight at 4°C; and incubated with
peroxidase-conjugated goat anti-rabbit Fab fragments for 1 hour. Peroxi-
dase reaction was developed with 3,3′-diaminobenzidine (DAB).
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Immunoprecipitation of TrpRS Labeled In Vivo with
[ 35S]Methionine or [ 32P]Orthophosphoric Acid
Original MDBK and sublines treated with TrpRS inhibitors, trypt-
amine, or tryptophanol [20] were labeled in vivo with 35S-methionine
for 2.5 or 24 hours and tryptamine-resistant HeLa A cells [21] were
labeled for 4.5 hours. Anti-TrpRS serum and nonimmune sera were
used for immunoprecipitation of culture medium (HeLa A), mono-
specific polyclonal antibodies were used for immunoprecipitation
of MDBK cell extracts insoluble in detergent (0.5% Triton X-100,
0.15MNaCl, 50mMTris-HCl pH 7.5, 2mMDFP at 0°C for 15min-
utes), and detergent-soluble cells fractions were immunoprecipitated
by anti-TrpRS IgG as described [20]. Detergent-insoluble fraction was
washed three times with buffer for lysis, suspended in 5 mM Tris-HCl
pH 7.5 and 2 mM DFP, and spun. Supernatants used for immuno-
precipitation. Labeling with [32P]orthophosphoric acid was conducted
as described [20,21]. Detergent-soluble (2.5 or 48 hours of labeling)
or postmitochondrial (5 hours of labeling) extracts of MDBK and
tryptamine-treated sublines were immunoprecipitated with rabbit poly-
clonal antiserum or IgG or monospecific antibodies to TrpRS.
TrpRS Enzymatic Activity in MDBK Cells and
Human Tissues
Human tissue extracts and cell extracts were assayed in tryptophan-
dependent [32P]PPi-ATP exchange in buffer containing varied tryp-
tophan concentrations (0-25 μM), 50 mM Tris-HCl pH 7.5, 10 mM
MgCl2, 0.2% dialyzed gelatin, 10 mM ATP, 3 mM PPi, and [
32P]PPi
(6.9 mCi/mmol; Amersham, Buckinghamshire, United Kingdom).
Postmitochondrial human extracts (400 μl each) were dialyzed before
the assay against 50 mM Tris-HCl pH 7.5, 2 mM 2-ME, and
2.5 mM DFP (1 L) overnight and then against the buffer change (1 L
for 3 hours at 4°C). The dialyzed tissue extracts (100 μg) were incubated
in buffer for [32P]PPi-ATP exchange (200 μl for 12 minutes at 37°C)
and then filtered and counted as described [20]. The count of control
probes incubated without tryptophan for each extract was deducted.
Phospho–Amino Acid Analysis
After in vitro phosphorylation with [γ32P]ATP, TrpRS was analyzed
by PAGE. After autoradiography, the 32P-TrpRS ∼60-kDa bands were
excised from the gel, boiled in 1% SDS (1 ml for 15 minutes), and
spun, and supernatants were precipitated by acetone (5 ml). The dried
pellets were hydrolyzed in 6 M HCl (1 ml for 90 minutes at 110°C).
The hydrolysates were lyophilized and separated in two dimensions on
thin-layer cellulose plates (Kodak, Rochester, NY) using electrophoresis
in acetic acid/pyridine/water (87:2:911) at 1000 V in the first dimen-
sion and chromatography in n-butanol/formic acid/isopropanol/water
(4:1:1:1) in the second dimension. The hydrolysates were also separated
on thin-layer cellulose plates using electrophoresis in two dimensions as
described [12,33]. Mobility of phospho–amino acid standards (Sigma)
was visualized with ninhydrin.
Results and Discussion
Cancer Sera–Inducible Phosphorylation of TrpRS and
Its Proteolytic Fragments
The cohort of cancer patients with solid malignant tumors of differ-
ent types, metastatic disease and leukemia (Tables W1 and W2) and
TBR revealed serum-inducible TrpRS phosphorylation (Figure 1).
Blood sera of 11 of 15 healthy volunteers showed no stimulation of
TrpRS phosphorylation (Figure 1). The serum of patient recovered
after acute meningitis was abolished by endogenous TrpRS phosphory-
lation. The serum-inducible TrpRS phosphorylation was demonstrated
in three healthy donors who have been later diagnosed with CRC, PC,
or leukemia and in one healthy donor with papillomatosis (Table W3).
Thus, serum-inducible TrpRS phosphorylation can be revealed years
before clinical diagnosis of cancer.
Anti-TrpRS Sera as Chaperon-like Molecules to Restore
Phosphorylation of Full-length TrpRS
To control the specificity of TrpRS phosphorylation, the polyclonal
anti-TrpRS rabbit serum was examined, and it was found that it stimu-
lated (10-fold) the phosphorylation of exogenous TrpRS in the presence
of 2-ME (Figures 2A andW1). 2-MEwas used to reduce disulfide bonds.
2-ME inhibits TrpRS phosphorylation, whereas anti-TrpRS serum-
inducible phosphorylation is unaffected by 2-ME (Figure 2B). Con-
sequently, anti–serum-inducible phosphorylation of full-length TrpRS
was prevented in the absence of 2-ME (Figure 2B). In earlier studies,
2-ME inhibited phosphorylation of the microsomal polypeptides in vitro
(>90% inhibition at 40 mM 2-ME) [34]. Both bTrpRS and hTrpRS
contain six cysteine residues involved in the formation of disulfide
bonds between two subunits. Cys62 is suggested to play a role in TrpRS
angiogenic activity [35]. There are 24 serine-containing sites predicted
for phosphorylation [36] in the hTrpRS sequence (GenBank accession
no. EAW81703.1). In hTrpRS, Ser272 is close to Cys274 (Ser276 and
Cys278 in bTrpRS). Some proteins can be denatured by 2-ME through
its ability to cleave disulfide bonds. Therefore, the 2-ME–induced reduc-
tion of disulfide bonds in TrpRS inhibits its phosphorylation, whereas
anti-TrpRS serum plays a role of chaperon refolding TrpRS and re-
activating its phosphorylation. Note that the use of buffer containing
2-MEmay lead to erroneous results if not freshly prepared. Specifically,
the repeated freeze-thaw cycles of 2-ME containing PK buffer diminish
the anti-TrpRS serum-inducible effect.
Effect of Anti-TrpRS Serum on Phosphorylation of
TrpRS Forms
Stimulation of phosphorylation of 30- and 14-kDa TrpRS proteolytic
fragments by antisera specific to TrpRS is 2-ME independent. After
dialysis of TrpRS (48 hours), phosphorylation of the 30- and 14- to
17-kDa peptides is stimulated effectively by anti-TrpRS rabbit antisera
but not nonimmune rabbit sera (Figure 3, B and C). Anti-TrpRS serum–
stimulated phosphorylation of these fragments has been achieved in the
minimal buffer containing Mn2+ and protease inhibitors (Figure 3C).
Phosphorylation of 60- and 40-kDa TrpRS was not stimulated by anti-
TrpRS or nonimmune rabbit sera in the absence of 2-ME. Anti-AFP
and anti-TF polyclonal rabbit sera exerted no effect on TrpRS phosphory-
lation with or without 2-ME (Figure 3B). The ∼100-kDa rabbit serum
proteins were phosphorylated in the presence of TrpRS in anti-AFP,
anti-TF, and nonimmune rabbit sera, whereas anti-TrpRS and TBR sera
revealed no phosphorylation of 100-kDa serum proteins (Figure 3D).
Phosphorylation of 20-kDa TrpRS Proteolytic Polypeptide Is
Stimulated by Anti-TrpRS IgG and Cancer Sera
Anti-TrpRS IgG abolished phosphorylation of 60-kDa TrpRS (Fig-
ure 1A) but stimulated phosphorylation of the ∼20-kDa fragment in
the presence of 2-ME (50 mM; Figure 4A). This fragment is not pro-
duced by IgG-associated hydrolysis as evident from Coomassie staining
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(Figure 4A). Phosphorylation of this fragment is stimulated also by
TBR serum and sera from six of seven cancer patients but not by sera
from healthy donors (Figure 4B). PK assay is conducted in the presence
of protease inhibitor. No accumulation of the 20-kDa fragment was
detected by Coomassie staining after incubation with cancer sera (Fig-
ure 4B). In previous studies, the bTrpRS fragments were produced by
limited proteolysis with trypsin by the following scheme: 2 × 60 kDa→
2 × 40 kDa → 2 × 24 kDa → 2 × 14 kDa. The carboxy-terminal
40-kDa fragment and amino-terminal 20-kDa fragments produced
were also due to endogenous proteolysis [37]. The activity of full-length
bTrpRS in aminoacylation is inhibited by anti-TrpRS polyclonal anti-
bodies. However, bTrpRS activity in aminoacylation was unaffected
by binding of antibodies to N-terminal 20-kDa TrpRS fragment. In
our earlier study, some sera of cancer patients contained anti-TrpRS
IgG [38]. Thus, anti-TrpRS IgG can affect phosphorylation of TrpRS
in vivo in human. Serum-stimulated phosphorylation sites were revealed
also in another translational protein—eukaryotic translation initiation
factor 4GI [39]. Thus, anti-TrpRS IgG is suggested to be a factor or
cofactor in the stimulation of TrpRS phosphorylation by cancer sera.
All molecular chaperones known to date are protein molecules whose
three-dimensional structures are believed to play a key role in the mecha-
nism of substrate recognition and subsequent assistance to folding. A
previous study demonstrated that the monoclonal antibody to bTrpRS
is able to disaggregate helical fibrils self-assembled by TrpRS N-terminal
peptide [23]. In the stimulation of TrpRS phosphorylation, human can-
cer sera, TBR serum, as well as anti-TrpRS antisera and IgG may work
as chaperone-like molecules to play a role in the molecular recognition
of TrpRS and subsequent assistance in refolding.
Casein Works as Chaperons for TrpRS in the Presence of 2-ME
Casein is examined here as a possible substrate for TrpRS-associated
PK. Surprisingly, the chaperone-like activity in refolding of TrpRS by
casein is demonstrated in the presence of 50 mM 2-ME, which pro-
motes the dissociation of TrpRS subunits (Figure W2A). Such activity
was not detected in BSA, protein A, and histones (FigureW2, A and B).
A cyclic AMP (cAMP)-independent weak phosphorylation of casein is
catalyzed by TrpRS–PK (Figure W3). Most, but not all, of the casein
proteins exist in a colloidal particle known as the casein micelle. αs-
Casein not only prevents the formation of huge insoluble aggregates
but also inhibits accumulation of soluble aggregates of appreciable
size. Unlike other molecular chaperones, this protein solubilizes hydro-
phobically aggregated proteins. This protein seems to have some char-
acteristics of cold shock protein, and its chaperone-like activity increases
with a decrease in temperature [40]. α-Casein micelles show not only
molecular chaperone-like aggregation inhibition properties but also pro-
tein refolding activity from the denatured state [41]. TrpRS is susceptible
to aggregation in vitro and in the human brain [23].
Figure 1. Serum-inducible phosphorylation of purified bTrpRS (selected human and rabbit sera). (A) TrpRS endogenous phosphorylation
(auto) is stimulated by TBR serum but not serum of normal rabbit (N) in the presence of Mg2+, Mn2+, and 2-ME. Anti-TrpRS IgG totally
abrogated (60 and 30 kDa) or decreased (50 kDa) phosphorylation of TrpRS and its proteolytic polypeptides. (B-D) Serum-inducible TrpRS
phosphorylation. (B) Phosphorylation of 30-kDa TrpRS polypeptide in the presence of blood sera from healthy donors (C) (donor 1 [C1], F;
donor 2 [C2], M; donor 3, M [C3]) and cancer patients (T) (stomach cancer, multiple metastases in liver, bladder, ascites, F [T1]; chondroma,
rib no. 4 right side, fast-growing, M [T2]; testicular seminoma, left side, stage 3, M [T3]; lung cancer, upper lobe of left lung, stage 3,
M [T4]; cancer colli uteri [CC], stage 3, F [T5]; bladder cancer, stage 3, M [T6]; lung cancer, right lung stage 4, metastasis in spinal cord,
M [T7]). (C) Comparison of representative phosphorylation profiles of TrpRS in the presence of sera from donor 3, M (C3) and patient with
stomach cancer, multiple metastases in liver, bladder, ascites, F (T1). (D) TrpRS phosphorylation after addition of selected human sera.
Healthy donor, M (C2); uterine cancer, underwent radical surgery, radiation therapy 8 years before testing, no cancer at the time of testing,
F, RBP (UC); healthy donor (papilloma removed), F (Pap); healthy donor, acute meningitis, 1.5 years before the testing, M (MG); healthy
donor, M, FPT (C4); gallbladder disease at the time of testing, F, YSM (GBD); colorectal cancer, after surgery, F, LPM (CRC); leukemia
(L); squamous cell lung cancer, central location of right lung, stage 4, moderately differentiated, M (T8); urinary bladder cancer, recurrent,
stage 3, F (T9); stomach cancer, F (T10); stomach cancer, 4 stage, M (T11). Then, 12.5% SDS-PAGE followed by autoradiography. F indicates
female; M, male.
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Synergistic Effects of cAMP and 2-ME on
TrpRS Phosphorylation
A possible cAMP dependence of TrpRS is further examined in the
phosphorylation assay. cAMP (100 μM) in combination with 2-ME
(50 mM) abolishes endogenous TrpRS phosphorylation (Figure 2A),
whereas cAMP alone has no such effect (Figure W3). 2-ME alone
inhibits TrpRS phosphorylation but to a lesser extent than in com-
bination with cAMP (Figure 2, A and B). Apparently, cAMP enhances
the effect of 2-ME. 2-ME stimulates oxidative dissociation of TrpRS
subunits with concomitant impairment of TrpRS phosphorylation.
cAMP enhances 2-ME–induced inhibition of TrpRS phosphorylation
that was partially restored by chaperon-like effects of anti-TrpRS serum
and casein (Figures 2, A and B, and W2). The synergistic effect of
cAMP and 2-ME can be explained by cAMP-mediated intersubunit
disulfide cross-linking that was earlier proposed for Escherichia coli pro-
tein [42]. Incorrect disulfide TrpRS intersubunit cross-linking may lead
Figure 2. Serum-inducible TrpRS phosphorylation (rabbit sera). (A) Anti-TrpRS rabbit serum (TS) stimulates bTrpRS phosphorylation in
the presence of 50 mM 2-ME. cAMP (100 μM) repressed TrpRS-PK and anti-TrpRS serum-inducible TrpRS phosphorylation. Left and right
panels show 17 and 5 hours of exposure of x-ray films, respectively. (B) Phosphorylation of purified full-length bTrpRS inhibited by 2-ME
(50 mM) and stimulated by anti-TrpRS serum (TS) in the presence of 2-ME (50 mM), 30 minutes of x-ray film exposure. (C) TrpRS secretion
into rabbit sera. Anti-TrpRS (TS1 and TS2) and nonimmune (N1, N2) rabbit sera (10 μl each) analyzed by 12.5% SDS-PAGE followed by
immunoblot with TS antiserum (1:100). Immunoperoxidase reaction developed with DAB. All four sera contained TrpRS (N2 > N1 >
TS1 = TS2). (D) Alkaline phosphatase from E. coli (AP) inhibits phosphorylation of TrpRS and its 14-kDa peptide. TrpRS (2 μg) incubated
with 2.5 μl of AP (72 U/mg, 215 U/ml, 40 minutes at 25°C) and then phosphorylated in PK buffer (20 μl, 20 mM Tris-HCl pH 7.2, 2 mMMnCl2,
5 mMMgCl2, 1 mM 5′AMP, 3 mM DFP, 3 μl of [γ-
32P]-ATP [2-3000 Ci/mmol, 1 mCi/0.2 ml]). (E) TrpRS immunoprecipitation with TBR serum
followed by phosphorylation with [γ-32P]ATP (see Materials and Methods section). (F) Rat embryo washed in Hank’s buffered solution, cut
with scissors in the same buffer, washed, homogenized in glass/glass homogenizer in 5 ml of lysis buffer (0.5% Triton X-100, 0.14 M NaCl,
50 mM Tris-HCl pH 7.2, 3 mM DFP, 3 mM PMSF, 0.5% aprotinin) with DFP (2 μl), and spun. The supernatant (600 μl) was preincubated
with cocktail of nonimmune sera N1 and N2 (6 μl of each serum), overnight at 4°C, and 10% protein A S. aureus (50 μl) was added in
RIPA buffer for 30 minutes at 37°C, spun, and washed in the same buffer. The supernatants (100 μl/probe) were incubated with TS2 or
N rabbit sera (3 μl) overnight; 10% protein A S. aureus (20 μl) was added to each probe for 40 minutes at 37°C. (G) Purified bTrpRS immuno-
precipitated by rabbit polyclonal anti-TrpRS serum (TS) or TBR serum. Immunoprecipitation with nonimmune rabbit serum (N) was un-
detectable. After the reaction (100 μl of PBS for 50 minutes at 37°C), immunoprecipitates were incubated with 20 μl of 10% protein A
S. aureus (immunoprecipitation) suspended in lysis buffer (0.5% Triton X-100, 0.14MNaCl, 50mM Tris-HCl pH 7.2, 3mMDFP, 3mMPMSF,
0.5% aprotinin) for 30 minutes at 37°C. Immunoprecipitates (pellets) were washed three times with 1 ml of ice-cold RIPA buffer (0.15 M
NaCl, 0.01 M sodium phosphate, pH 7.2, 1% NP-40 [Sigma], 1% sodium deoxycholate [Sigma], 0.1% SDS, and 3 mM PMSF). Pellets were
suspended in 1 ml of PK buffer (20 mM Tris-HCl [Calbiochem], pH 7.2, 2 mMMnCl2 [Fluka], 1 mM 5′AMP, 50 mM 2-ME, and 50 μM EDTA)
and spun, and each pellet was suspended in PK buffer (20 μl) with 10 μCi of [γ-32P]-ATP (2-3000 Ci/mmol, 400 μCi/0.1 ml of water) for
10 minutes at 37°C. Laemmli sample buffer (boiling for 5 minutes) was analyzed on 4% SDS-PAGE (immune complex) or 10% SDS-PAGE.
TrpRS was phosphorylated without previous immunoprecipitation (10% SDS-PAGE; right). X-ray exposure for 21 hours (immunoprecipita-
tion) and 2 hours (TrpRS). (H) Two-dimensional phospho–amino acid analysis. 32P-TrpRS was excised from gel (10% SDS-PAGE) and ana-
lyzed using electrophoresis (9 cm from start (or)) in the first dimension (I) and chromatography in the second dimension (II). Phosphoserine
(p-ser) is detected in 32P-TrpRS and serum-inducible 32P-TrpRS. Ninhydrin-stained phosphothreonine and phosphotyrosine are encircled.
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in aggregation, which impairs TrpRS phosphorylation. Cerebrospinal
fluid cAMP levels are increased in AD [43]. TrpRS aggregates were
detected in the brain of patients with AD [23].
Effect of Tryptophan on Phosphorylation of TrpRS Fragments
The TrpRS substrate, tryptophan, protects TrpRS from dissociation
and inactivation [44], whereas tryptophan analogs and competitive
TrpRS inhibitors, tryptamine and tryptophanol, induce TrpRS aggre-
gation in vivo [20]. Therefore, a possible effect of tryptophan on TrpRS
phosphorylation was examined in the presence of 2-ME. Phosphoryla-
tion of 20-, 25-, 30-, and 40-kDa TrpRS fragments seems to be stimu-
lated by tryptophan (Figure 3A). In a previous study, the polypeptides
with molecular masses of approximately 40 and 30 kDa were revealed
in elastase and CNBr-generated bTrpRS fragments, respectively [45].
A common increase of free plasma tryptophan in human cancer may
be implicated as cofactor in serum-inducible TrpRS phosphorylation.
Secreted TrpRS in Rabbit Sera
TrpRS was secreted [24]. To explore the possibility that TrpRS-PK
is involved in serum-inducible phosphorylation, immunoblot analysis
of TrpRS was conducted. The ∼58-kDa TrpRS is detected in two
Figure 3. Anti-TrpRS serum stimulates phosphorylation of TrpRS proteolytic fragments but not components of ARS complex. (A) Phos-
phorylation of TrpRS polypeptides stimulated (arrows) or inhibited (arrow with asterisk) by 10 μM tryptophan: autoradiography (1, 2) and
Coomassie staining (1′, 2′). (B) Effect of rabbit antisera to bTrpRS (TS), AFP, and Thomsen-Friedenreich antigen (TF) on phosphorylation of
the 30- and 14-kDa polypeptide. (C) Serum-inducible phosphorylation of 30- and 14-kDa polypeptides with anti-TrpRS rabbit serum (TS2) but
not with nonimmune rabbit serum (N) in the presence of protease inhibitors, 3 mMDFP or 3 mM PMSF, 2 mMMnCl2, and 20 mM Tris-HCl,
pH 7.2. (D) Phosphorylation of 100-kDa endogenous rabbit serum polypeptides in the presence of TrpRS. Rabbit sera used were as follows:
RSV-induced tumor (TBR), anti-TrpRS (TS1, TS2), anti-TrpRS IgG, nonimmune (N1, N2), anti-AFP, and anti-TF. (E) Decreased phosphorylation
of the components of multienzyme ARS complex (WC; 20 μg/sample) in the presence of anti-TrpRS (TS1, TS2) or nonimmune rabbit (N1,
N2) sera (2 μl/sample). Phosphorylated GlnRS and MetRS (∼105 kDa) assigned as described [47]. A (left) and B to E show autoradiographs.
TrpRS (1, 2, or 20 μg) and rabbit sera (2 μl) are included in samples (indicated).
Figure 4. Phosphorylation of 20-kDa TrpRS proteolytic polypeptide
is stimulated by anti-TrpRS IgG (A) and cancer sera (B). Sera obtained
from the human cohort (B) described in the legend to Figure 1B:
autoradiography (32P) and Coomassie staining (stain). Rabbit sam-
ples are shown in A and B (TBR); human samples are shown in
B (C1 to T7).
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nonimmune and two anti-TrpRS rabbit sera by anti-TrpRS poly-
clonal antibodies. The TrpRS level is lower in anti-TrpRS sera than
in nonimmune rabbit sera (Figure 2C ).
Immunoprecipitation of TrpRS by TBR
TBR serum stimulates TrpRS phosphorylation (Figure 1A). More-
over, TBR serum immunoprecipitates PK associated with TrpRS (Fig-
ure 2, E and G ). TrpRS-PK is immunoprecipitated also from rat
embryo by anti-TrpRS serum but not by nonimmune rabbit serum
(Figure 2F ). Because TBR serum contains antibodies against RSV
virion structural proteins, it may contain antibodies to TrpRS that
packed in RSV virion with its cognate tRNAtrp [9]. Endogenously
phosphorylated TrpRS and TrpRS immunoprecipitated by TBR
serum or anti-TrpRS serum contain phosphoserine (Figure 2H ). A
cross-immunoreactivity between TrpRS and src could also cause im-
munoprecipitation of TrpRS by TBR serum. To examine this possi-
bility, the TrpRS and src protein sequences have been compared.
Although no significant similarity between hTrpRS (GenBank acces-
sion no. EAW81703.1) and human c-src protein (GenBank accession
no. AAH11566.1) was detected, the 11-amino acid (aa) peptides
near the carboxyl termini of hTrpRS 399/SFMYLTFFLED/409 and
human c-src 511/TFEYLQAFLED/521 show 64% identity (7/11 aa).
This homologic peptide is adjusted and partially overlapped with
conformation-dependent TrpRS antigenic epitope that we previously
mapped at Asp409-Met425 [23]. The peptide lies 5 aa upstream of
the c-src major phosphorylation site Tyr527. This sequence is not pres-
ent in pp60 v-src (Swiss-Prot no. P00524.5) but is present in bTrpRS
(National Center for Biotechnology Information no. NP_776643.1).
Phosphorylation of pp60 c-src at Tyr527 suppresses its tyrosine kinase
activity and transforming potential [46]. Mapping of TrpRS epitope
in the region, which is similar to c-src sequence, suggests that anti-
TrpRS conformation-dependent antibody may bind c-src and modu-
late kinase activity specific to c-src major site Tyr527 responsible
for transformation.
Phosphorylation of Multienzyme Complex of ARS
Other ARS are also phosphoproteins. Therefore, it is of interest to
examine whether phosphorylation of synthetases of the ARS complex
was affected by serum. The multisynthetase core complex comprising
seven ARS underwent self-phosphorylation. The ARS complex from
rabbit liver possesses an endogenous PK activity (Figure 3E). Phosphory-
lation of the ∼100-kDa doublet is detected in the complex in agreement
with a previous study [47]. These proteins are attributed as glutaminyl-
tRNA synthetase (GlnRS) and methionyl-tRNA synthetase (MetRS).
The phosphorylation of GlnRS and MetRS was suppressed by anti-
TrpRS rabbit sera and abolished by nonimmune rabbit sera. Phosphory-
lation of other components of the multienzyme complex was unaffected
by the rabbit sera. In an earlier study, PKC phosphorylated glutamyl-
tRNA synthetase but not MetRS and GlnRS [29]. Phosphorylation
in vivo is accompanied by a 38% ± 10% reduction in aminoacylation
activity of partially purified glutamyl-tRNA synthetase assayed in vitro.
Serine phosphorylation of a multisynthetase complex component,
glutamyl-prolyl tRNA synthetase, by cyclin-dependent kinase 5 regulates
translational control [48].
Histone-Specific PK in Human Sera
In a previous study, TrpRS-specific PK phosphorylates histones [12].
Therefore, it is of interest to examine phosphorylation of histones in the
presence of human sera affecting TrpRS phosphorylation (Tables W4–
W6). Histones underwent phosphorylation in the presence of earlier
tested (Figure 1) and yet untested human sera. Donor sera, which do
not affect TrpRS phosphorylation, phosphorylate strongly histones,
mainly histone H2B (Figure 5, A-C ). Earlier tested sera of donors with
gallbladder disease (GBD) and papilloma (Pap) and TrpRS-untested
sera of patients with psoriasis (Psr) phosphorylate also histone H4.
Endogenous phosphorylation of histones was undetectable (Figure 5E).
Endogenous phosphorylation of serum polypeptides of low molecular
mass overlapping with the molecular mass of histones H2A, H2B, H3,
and H4 is commonly undetectable (Figure 5D) unless serum proteins
are heavily proteolyzed on repeated freeze-thaw cycles. Normal human
serum partially loses histone-specific PK activity on repeated freeze-thaw
cycles (second to third cycles). Phosphorylation of histones by cancer
sera and serum of healthy donor diagnosed later with CRC (C4) is low
or undetectable (Figure 5, A-C). The histone-specific PK serum activity
is low in 8 but normal in 2 of 10 hospitalized patients with pneu-
monia (Figure 5, C and E ). Sera of patients with acute myocardial
infarction (3/3 patients) and stomach ulcer (1 patient) had undetectable
histone-specific PK activity.
Histone-Specific PK in Rabbit Sera
Phosphorylation of histones was examined also in the presence of
nonimmune rabbit sera, anti-TrpRS polyclonal rabbit sera, anti-TrpRS
IgG, anti-AFP polyclonal rabbit antiserum, and anti-TF antigen poly-
clonal rabbit serum (Figures 6 and W3). Nonimmune sera, anti-AFP,
and anti-TF sera strongly phosphorylated histones in the presence of
Mg2+ and Mn2+. Phosphorylation of histone H2B in the presence of
Mg2+ alone was lower than in the presence of Mn2+ alone and was high-
est in the presence of both Mg2+ and Mn2+ (Figure 6D). Phosphoryla-
tion of histone H2B with anti-TrpRS rabbits was low or undetectable
(Figure 6D). Anti-TrpRS IgG showed no histone-specific PK activity in
the presence of Mg2+ and Mn2+ (Figures 6E and W3). Thus, in con-
trast to TrpRS serum-inducible phosphorylation, histone phosphoryla-
tion has not been induced by anti-TrpRS sera but was stimulated by
other rabbit sera, which do not visibly affect TrpRS phosphorylation.
These data indicate that a link exists between TrpRS and histones in
serum-inducible phosphorylation.
Endogenous Human Serum Phosphorylation
To control the “background” signal in human serum phosphory-
lation, endogenous phosphorylated proteins were examined in the
presence of Mg2+ and Mn2+ and in the absence of exogenous sub-
strates. The ∼100-kDa phosphopolypeptide/s was found to be pres-
ent in sera of healthy individuals and absent in most cancer patients
(Figure 5E , arrows).
Immunoprecipitation of 35S In Vivo–Labeled TrpRS from
Culture Medium
To examine if TrpRS is secreted by cancer cells, the culture medium
of 35S-labeled tryptamine-treated subline HeLa-A expressing TrpRS
with a longer half-life (>5 hours) than original HeLa (<2 hours)
[21] was immunoprecipitated. Several labeled fragments were immuno-
precipitated by anti-TrpRS antiserum fromHeLa-A cell culture medium
after in vivo metabolic labeling (4.5 hours) with [35S]methionine
(Figure W4A). These data confirm that TrpRS is secreted by human
cancer cells.
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Refolding of TrpRS Aggregated and Labeled In Vivo
Refolding and stability of TrpRS from detergent-insoluble fraction.
Here, in vitro refolding of TrpRS-labeled in vivo was studied in the
original MDBK cell and sublines treated with tryptophan analogs
[20]. After in vivo labeling of MDBK cells with [35S]methionine
(24 hours), detergent-insoluble extracts were incubated with anti-
TrpRS monospecific antibodies or with the immune complex of
purified unlabeled bTrpRS with anti-TrpRS monospecific antibodies
(TrpRS–anti-TrpRS). The level of 35S-TrpRS immunoprecipitated
with TrpRS–anti-TrpRS immune complex exceeds significantly the
level of immunoprecipitation with antibodies alone. Apparently,
renaturation of aggregated TrpRS is stimulated by chaperone-like
or cochaperone activity of TrpRS–anti-TrpRS immune complex in
detergent-insoluble fraction, which contains aggregated proteins
(Figure W4B). It seems that the level of TrpRS aggregation is under-
estimated in conventional immunoprecipitation that uses antibodies that
are not pretreated with antigen. After 24 hours of labeling (detergent-
insoluble fraction), TrpRS was undetectable or was decreased in the
treated cells, whereas TrpRS level was unchanged in control MDBK
in comparison with the level detected after 2.5 hours of labeling (Fig-
ure W4B). These data indicate that TrpRS turnover increased, whereas
its half-life decreased after prolonged tryptamine or tryptophanol treat-
ment of MDBK. Both tryptamine and tryptophanol are carboxyl
analogs of tryptophan and TrpRS inhibitors. The bTrpRS dissociation
constants, K s calculated from the Scatchard plots are 0.95 μM for
tryptophan and 1.8 μM for tryptamine [44].
TrpRS catalyzed tryptophan-dependent ATP-[32P]PPi exchange.
To correlate TrpRS enzymatic activity with TrpRS aggregation and
phosphorylation, the ATP-PPi exchange was examined in detergent-
soluble cell extracts of untreatedMDBK and tryptamine-treated MDBK
Figure 5. Serum-inducible phosphorylation of histones and endogenous phosphorylation of p100 in selected human samples. (A) Samples
of healthy women (C1 and C6); cancer serum samples (T1-T7) of females (F) andmales (M) correspond to numbers as in Figure 1C: stomach
cancer (T1), multiple metastases in liver, bladder, ascites, F; chondroma, rib no. 4, right side, fast-growing, M (T2); testicular seminoma, left,
stage 3, M (T3); lung cancer, upper lobe of left lung, stage 3, M (T4); CC (cancer colli uteri) stage 3, F (T5); bladder cancer, stage 3, M (T6);
lung cancer, right lung stage 4, metastasis in spinal cord, M (T7). Upper panel, 32P autoradiography of 100-kDa phosphopolypeptides; lower
panel, histone phosphorylation. (B) Histone phosphorylation by selected human sera revealed by 32P autoradiography (upper panel) and
Coomassie staining (lower panel) of the same SDS-PAGE. The positions of histones H2A, H2B, H3, and H4 are indicated at the side. Serum
samples of healthy individuals: C1 (F); C2 (M); C7 (M); C8 (F); C9 (M); leukemia (L); squamous cell lung cancer, central location of right lung,
stage 4, moderately differentiated, M (T8); urinary bladder cancer, recurrent, stage 3, F (T9); stomach cancer, F (T10); stomach cancer,
4 stage, M (T11); uterine cancer, 8 years before the testing, after surgery, after radiation therapy, no cancer, F (UC); gallbladder disease,
F (GBD). Histone H4 phosphorylation (asterisk); colorectal cancer, after surgery, F (CRC). Probe included 20 μg of histones (10mg/ml, H2SO4
extraction), serum (2 μl/sample), 18 μl of PK buffer (2-ME, Mn2+, 5′AMP), [γ-32P]ATP (5 μCi/sample for 15 minutes at 37°C). (C) 32P auto-
radiography of histone phosphorylation by selected sera of noncancer individuals. Noncancer individual, papilloma removal, papillomatosis
in family (mother, sister), F (Pap); noncancer individual, cervical erosion 8 to 9 years before testing, papillomas, papillomatosis in family,
F (C10); healthy individual, M (C2); healthy individual, M (C4); gallbladder disease, F (GBD), GBD in family (mother); healthy individual, acute
meningitis 1.5 years before the testing, M (MG); psoriasis case 1 (Psr1), psoriasis case 2 (Psr2); pneumonia, M (PN). (D) 32P autoradiography
of serum phosphorylation without exogenous histones. Note that none or only marginal phosphorylation of low–molecular weight peptides
of 14 to 18 kDa was detected. Healthy individual, M (C4); individual with gallbladder disease, F (GBD). (E) Comparison of serum-inducible
phosphorylation of endogenous p100 and exogenous histone H2B by selected representative samples from a healthy individual (C1),
a pneumonia case (PN), and individuals with OVC and CC. 32P autoradiography of phosphorylation with (+) or without (−) histones.
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subline. The enzymatic activity is ∼2.5-fold higher in tryptamine-treated
cells compared with control cells (Figure W5).
TrpRS refolding in detergent-soluble fraction of cells treated with
TrpRS inhibitors. In the same treated cells, the amount of immuno-
precipitated 35S-labeled TrpRS (50-kDa excised band) is ∼10 times
higher compared with control cells after 2.5 hours of labeling (Figure 4,
T2 in panel B corresponds to TN3 in panel C , both indicated with
asterisks). A dramatic difference in 35S-TrpRS (2.5 hours of labeling)
immunoprecipitated from detergent-soluble fractions is detected be-
tween cells treated with inhibitors and control cells when immune com-
plex (anti-TrpRS IgG with purified unlabeled TrpRS) was used for
immunoprecipitation (Figure W4C). When anti-TrpRS IgG was used
alone for immunoprecipitation, the difference between control and
treated was less dramatic in 35S-TrpRS level because TrpRS–anti-
TrpRS IgG enhances TrpRS immunoprecipitation in treated cells and
decreases in control. These results suggest that treated cells contain a
high amount of aggregated TrpRS, which were disaggregated by the
TrpRS–anti-TrpRS IgG immune complex. The disaggregating ability
of mAb to TrpRS was demonstrated in a previous study [23]. The level
of TrpRS aggregation in cells treated with tryptamine or tryptophanol
is underestimated by conventional immunoprecipitation. Thus, the
proportion of enzymatically inactive TrpRS in tryptamine-treated
cells may be higher than 75%, a percentage estimated using conven-
tional immunoprecipitation with antibodies alone (Figure W4) and
tryptophan-dependent ATP-PPi exchange (Figure W5).
Equilibrium of phosphorylated, enzymatically active, and 35S-labeled
TrpRS. Analysis of enzymatic activity (AT-PPi exchange), 35S-labeled,
and 32P-labeled TrpRS in control MDBK and cells treated with TrpRS
inhibitors reveals that a significant proportion of TrpRS (75%) is
enzymatically inactive and, at the same time, nonphosphorylated in
treated cells (Figure W5). The level of 32P-TrpRS immunoprecipitated
from the detergent-soluble fraction of control MDBK cells is reduced
after incubation with TrpRS–anti-TrpRS, suggesting that control cells
contain no aggregated phospho-TrpRS (Figure W5A). Phosphorylated
TrpRS is detected at a higher level in the detergent-soluble fraction
compared to postmitochondrial fraction (Figure W5B). 32P TrpRS
detected in the postmitochondrial fraction of treated cells but was
undetectable in the control MDBK. Alkaline phosphatase abolished
TrpRS in vivo phosphorylation (Figure W5A). It has become in-
creasingly clear in recent years that amino acids can stimulate a signal
transduction pathway resulting in the phosphorylation [49]. The pres-
ent data show that amino acid analogs can effect phosphorylation
in a tryptophan competitive manner. The effects of TrpRS analogs
are physiology relevant because tryptamine presents in human blood
and tissue [50,51]. The epidemiology data show that AD and cancer
strike rarely the same person [52]. Taken together, the tryptamine-
induced AD model of neurodegeneration [22,24] and present data
(Figure W4) prompt the suggestion that the chaperone-like disag-
gregating activity of TrpRS–anti-TrpRS immune complex may prevent
AD in cancer patients. Tryptamine and tryptophanol induce accumu-
lation of aggregated, nonphosphorylated, and enzymatically inactive
TrpRS in cells.
Figure 6. Effect of magnesium (Mg2+) and manganese (Mn2+) on histone phosphorylation by immune and nonimmune rabbit sera. Sera
(2 μl) of rabbits immunizedwith TF antigen, AFP, bTrpRS (TS1 and TS2) and nonimmune rabbits (N1 and N2) used for in vitro phosphorylation
of purified histones with [γ-32P]ATP in the presence of Mg2+ or Mn2+ or both Mg2+ and Mn2+ (Mg + Mn): Coomassie staining (A, C) and
32P labeling (B, D). A and B show high–molecular weight polypeptides (≥100 kDa), C and D show low–molecular weight polypeptides
(14-18 kDa) at 15% SDS-PAGE. Arrows point at Mn2+-dependent phosphorylation, and asterisks indicate Mg2+-dependent phosphoryla-
tion of serum polypeptides (A, B). H2B and H4 are exogenous histones (C, D). (E) Low level of IgG-independent anti-TrpRS serum-inducible
(TS2) histone phosphorylation (32P). Positions of histones H1, H2B, and H4 are also indicated. Autophosphorylation of anti-TrpRS IgG,
histones, and 14- to 18-kDa endogenous serum polypeptides is undetectable.
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Mechanisms of tryptamine activity in connection with TrpRS.
Tryptamine binds protein sulfhydryl groups but not disulfide bonds
in rat brain synaptic membranes [53]. N -ethylmaleimide modifies
cysteine residues and inhibits tryptamine binding to membrane pro-
teins. TrpRS is associated with plasma, mitochondrial, and vesicle
membranes [24]. On reaction with N -ethylmaleimide, the enzymati-
cally active dimeric bTrpRS dissociates into inactive monomeric sub-
units. The monomeric structure is stabilized by the blocking of the
–SH groups exposed during the dissociation with a half-life of dissocia-
tion ∼30 minutes [54]. The N -ethylmaleimide–treated dissociated
TrpRS subunits were aggregated [54]. The TrpRS peptide carrying
the –SH group was located near the binding site of tryptophan [55].
The enzyme at a concentration higher than 10 to 15 μM (∼1 mg/ml)
underwent polymerization and aggregation [44]. There is no direct
evidence indicating that tryptamine binds or modifies sulfhydryl
groups in TrpRS. Structural data clearly show that the mini-hTrpRS
N-terminal β-hairpin (residues 83-93) is defined in the tryptophanamide
(tryptophan analog)-ATP–bound complex and partially defined in the
tryptophan-AMP–bound complex but disordered in the Trp-bound
complex and in the free mini-TrpRS [56]. The tryptophanamide-
stimulated transition from the disordered state into the β-hairpin
conformation may be implicated in the TrpRS fibril formation and
aggregation [23,24]. The E. coli TrpRS is able to form tryptophanamide
[57]. The K i of tryptophanamide, which is a competitive inhibitor of
Bacillus stearothermophilus TrpRS with respect to tryptophan, was mea-
sured to be 2.5 × 10−6 M. Tryptophanamide (Figure W6), therefore, has
a higher affinity for the synthetase than the substrate tryptophan [58].
The structural data on tryptamine-TrpRS or tryptophanol-TrpRS com-
plexes are not available. Tryptamine binds to tryptophan binding site
in dimeric TrpRS, inactivates TrpRS, and mediates its aggregation
in vivo. In addition, the x-ray crystallographic structural analysis of trypt-
amine complexes with 3-methylcytosine and 7-methylguanine revealed
the prominent stacking interactions of tryptamine with the methylated
nucleic acid bases [59]. The biologic implication of these interactions
can be significant in connection with diminished capacity of DNA from
human and hamster cell sublines to bind the hTrpRS gene–specific
Figure 7. Phosphorylated TrpRS is immunoprecipitated from postsurgical human tissue samples. (A) Postmitochondrial extract (50 μg)
phosphorylation (9 μCi of [γ-32P] ATP/sample, 10 mM Mg2+ for 2 minutes at 37°C), termination (20 mM EDTA), and immunoprecipitation
(IP) with rabbit monospecific polyclonal antibodies to bTrpRS (1 hour). Immunoprecipitates of normal muscle from individuals with uterine
cancer stage 1 (1); normal uterine muscle (2); normal uterine muscle from individual with necrotic myoma (3); normal uterine muscle from
individual with CC (4); normal epithelium of uterine (5); normal epithelium from individual with necrotic myoma (6); epithelium of individual
with CC (7); normal placenta (8); liver from individual with hepatitis B/serum hepatitis (9); four cases of myomas (10-13) (myoma, 10; fibro-
myoma, 11; myoma of individual with endometrial cancer, 12; fibromyoma, 13); corpus uterine cancer, three cases (14-16); OVC, two cases
(metastatic ovarian cancer 1, 17; ovarian cancer 2, 18); and normal bovine liver (19) separated (12.5% Laemmli SDS-PAGE for 12 hours).
Different tissue sampleswere obtained from the same individual: 2 and 5, 3 and 6, and 4 and 7. (B) Immunoblot of postmitochondrial (1, 3, 5,
1′, 3′, 5′) and mitochondrial (2, 4, 6, 2′, 4′, 6′) extracts of OVC cases (3-6, 3′-6′) and normal placenta (1, 2, 1′, 2′) with anti-TrpRS antibodies.
Nitrocellulose membrane was stained with Coomassie blue (1-6) or incubated with antibodies (1′-6′). (C) Immunoblot of postmitochondrial
extracts (50 μg) from normal uterine muscle (4 cases) and myomas (4 cases) with anti-TrpRS antibodies. Tissues: normal muscle at uterine
cancer stage 1 (1), normal uterine muscle (2), normal uterine muscle at necrotic myoma (3), normal uterine muscle at CC (4), myoma (5),
fibromyoma (6), myoma at endometrial cancer (7), and fibromyoma (8). (D) Immunoblot of TrpRS from bovine pancreas (BP): purified TrpRS
(7 μg) or postmitochondrial extract (50 μg). Note that 32P-TrpRS was undetectable in BP postmitochondrial extracts under experimental
conditions (A). Blots developed with 4-Cl-1-naphthol (B) or DAB (C, D). Positions of TrpRS (arrows), serum albumin (SA), and protein markers
(numbers) are also indicated.
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probes in Southern blot DNA-DNA hybridization after the prolonged
tryptamine treatment [21]. The high amounts of steadily accumulated
tryptamine are not required to cause the cell death and TrpRS aggre-
gation. On the contrary, the rapid protein turnover with a half-life of
different proteins ranging from a few minutes to hours supports a hit-
and-run mechanism for tryptamine cytotoxicity.
Equilibrium of TrpRS Phosphorylation, Expression, and
Enzymatic Activity in Normal and Tumor Human Tissues
Endogenous TrpRS is analyzed in postsurgical tissue samples (n =
18). After in vitro phosphorylation with [γ-32P]ATP, 32P-TrpRS was
detected in tissue samples of human OVC (2 cases) and CC epithelium
but was not undetected in corpus uterine cancer, myomas, normal
placenta, and liver by immunoprecipitation with monospecific anti-
TrpRS antibodies (Figure 7A). TrpRS is phosphorylated in human
tissue extracts in a Mg2+-dependent mode. These data correlate with
immunoblot analysis demonstrating TrpRS increase in OVC and de-
crease in myomas compared with normal human tissues (Figure 7, B
and C ). Assay of enzymatic TrpRS activity in tryptophan-dependent
ATP-[32P]PPi exchange demonstrated the highest activity in both OVC
cases of five tested tissues (Table W7). Tryptophan-dependent ATP-
PPi exchange in OVC tissue extracts was two to three times higher than
in normal human placenta and liver. The lowest activity was detected
in uterine cancer (5.3 times lower than in placenta). The control sam-
ples contained normal bovine liver (Figure 7B, lane 19), bovine pan-
creatic tissue extract, and bovine purified bTrpRS (Figure 7D). In a
previous study, anti-TrpRS IgG antibodies were detected in serum of
patient with OVC [38]. In this study, serum of CC stimulated TrpRS
phosphorylation (T5, Figures 1 and 4) and did not contain histone-
specific PK (T5, Figure 5). OVC serum did not contain histone-specific
PK similar to other cancer sera (Figure 5E). These data demonstrate that
the level of hTrpRS phosphorylation correlate with TrpRS enzymatic
activity and protein expression at least in OVC and normal tissues.
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Table W1. TrpRS Phosphorylation Tested with Blood Sera of Healthy Individuals and
Cancer Patients.
No. Noncancer Individuals No. Cancer Patients
15 13
Table W3. TrpRS and Histones in Serum-Inducible Phosphorylation: Follow-up Study.
Diagnosis at Follow-up, y Follow-up, y Diagnosis at Testing TrpRS Phosphorylation Histones Phosphorylation
(A) Cancer diagnosed years after testing
(1) Acute leukemia (deceased) 6 Uterine cancer High Low
8-y after treatment
Disease free
(2) PC (deceased) 17 GBD High H2B+H4+
(3) CRC (deceased, 19 y) 15 None High Low
(B) Good prognosis for survival
(4) Disease free 20 CRC Normal Low
(C) Suspected, undiagnosed
(5) Prolapsed uterus, hysterectomy-ovariectomy 19;
papillomatosis; kidney cyst; leukocytes, urine (500 × 109/l)
20 Papilloma High Normal
Car accident, broken ribs–related hospitalization before acute leukemia was diagnosed in case 1, gallbladder removal (stones) before PC was diagnosed in case 2, and gallbladder removal before CRC was
diagnosed in case 4.
Table W2. Site and Stage of Cancer Tested for Serum-Inducible TrpRS Phosphorylation.
Code Site Stage
T1 Stomach cancer Multiple metastasis
T2 Fast-growing chondroma n/a
T3 Testicular seminoma 3
T4 Lung cancer 3
T5 CC 3
T6 Bladder cancer 3
T7 Lung cancer 4, metastasis
LPM CRC 4
L Leukemia n/a
T8 Lung cancer, squamous cell carcinoma 4
T9 Recurrent bladder cancer 3
T10 Stomach cancer n/a
T11 Stomach cancer 4
n/a indicates not applicable.
Figure W2. Casein and anti-TrpRS serum but not BSA, histones (A) or protein A (B), work as chaperons for TrpRS in the presence of
2-ME. TrpRS phosphorylated in PK buffer (50 mM 2-ME, 1 mM 5′AMP, 2 mM MnCl2, 5 mM MgCl2, 50 μM EDTA, 3 mM PMSF, 20 mM
Tris-HCl, pH 7.5, 1.5 μl of [γ-32P]ATP, 2000 Ci/mmol, 10 μCi/μl) with or without cAMP (100 μM), casein (20 μg), anti-TrpRS serum (TS1,
2 μl), BSA (20 μg), histones (20 μg each, two different extractions), and protein A (20 μg, purified by affinity chromatography; Pasteur
Institute of Epidemiology and Microbiology, St. Petersburg, Russia). Positions of rabbit serum albumin (SA) and protein markers (kDa)
are shown.
Figure W1. Counting of Cherenkov radiation (∼60-kDa bTrpRS):
anti-TrpRS serum-inducible TrpRS phosphorylation (TS1, 2 μl). PK
assay probe (20 μl) contained 20 μg of bTrpRS, 0.5 μM [γ-32P]ATP
(2000 Ci/mmol, 500 μCi/50 μl), and 50 mM 2-ME and incubated
for 15 minutes at 37°C. Bands were excised from the gel (12.5%
SDS-PAGE); see Figure 2A (no cAMP).
Figure W3. Casein and cAMP independence of TrpRS-PK activity
in absence of 2-ME. Incubation was in PK buffer (20 mM Tris-HCl,
pH 7.2, 2.5 mM MgCl2, 4 mM MnCl2, 3 mM DFP, [γ-
32P]ATP) with
or without histones (20 μg), casein (40 μg), TrpRS (10 μg), anti-
TrpRS IgG (IgG, 2 μl), anti-TrpRS rabbit serum (TS, 2 μl), and cAMP
(100 μM). Lower panel, Coomassie staining (stain); upper panel,
autoradiography (32P), x-ray film exposure for 40 hours. The molecu-
lar weights of proteins (15% SDS-PAGE) are indicated with arrows.
32P-TrpRS forms are indicated by asterisks (60, 40, 17, and 14 kDa
and low–molecular weight peptide [LMP]). Note that casein refold-
ing and cAMP-inhibitory effects are undetectable.
Table W4. Histone-Specific PK in Noncancer and Cancer Sera.
No. Noncancer Individuals No. Cancer Patients
1. TrpRS tested
13 13
2. TrpRS nontested
17 31
Table W5. Diagnosis of Noncancer Individuals Tested for Histone Phosphorylation.
Diagnosis No. Individual TrpRS Test
GBD 1 Increase
After acute meningitis 1 Decrease
Papilloma 1 Increase
Psoriasis 3 ND
Pneumonia 10 ND
Myocardial infarction 3 ND
Stomach ulcer 1 ND
ND indicates not determined.
Table W6. Sites of Cancer Cases Tested for Histone-Specific Serum PK.
Site No. Individuals
Soft tissue sarcoma 2
Brain tumor 1
Breast cancer 1
CC 2
Bladder cancer 3
Lung cancer 2
Osteosarcoma 1
Seminoma 1
Prostate cancer 1
Esophageal cancer 1
OVC 1
CRC 2
Stomach cancer 1
Cancer of unknown primary location 12
Serum-inducible TrpRS phosphorylation has not been tested for these cases.
Figure W4. TrpRS immunoprecipitation after in vivo labeling with [35S]methionine. TrpRS was immunoprecipitated from [35S]methionine
culturemedium (250 μl) of tryptamine-resistant humanHeLa-A subline [21] (A) or control and treatedMDBK cells (B, C). Immunoprecipitation
was performed with anti-TrpRS rabbit serum (TS, 10 μl), nonimmune rabbit serum (N, 10 μl), monospecific anti-TrpRS polyclonal antibodies
(4.5 μg/probe; B) or anti-TrpRS IgG (40 μg/probe; C). Labeling was during 4.5 hours (A), 2.5 and 24 hours (B), and 2.5 hours (C). Extracts were
insoluble in 0.5% Triton X-100 for 15 minutes at 0°C (B) and detergent-soluble (C) extracts (1% NP-40, 10 mM Tris-HCl, pH 7.5, 50 mM KCl,
0.1 mM DTT, 20% glycerol) were examined with anti-TrpRS antibodies or antibodies preincubated with unlabeled purified bTrpRS (12 or
20 μg/300 μl; B, upper) or at 0.4 mg/ml (C) overnight (4°C). In B, 35S-labeled extracts contain 2 × 106 cpm; in C, 7 × 104 cpm (1) or 4.5 ×
105 cpm (6) before immunoprecipitation.
Figure W5. TrpRS equilibrium (tryptophan-dependent ATP-[32P]PPi exchange and
35S and 32P immunoprecipitation) in control MDBK
(white columns) and tryptamine-treated subline TN3/T2 (black columns). (A and B) In vivo cell labeling with [32P]orthophosphoric acid
(54 mCi/200 μl, 185 pBq/mol). Immunoprecipitation of 1% NP-40–soluble (A) and postmitochondrial (B) extracts with anti-TrpRS poly-
clonal serum (A) and monospecific anti-TrpRS antibodies (B). Equal 32P-radioactivity (48 hours of labeling) was incubated with anti-TrpRS
serum (10 μl) or preincubated anti-TrpRS serum (10 μl + unlabeled TrpRS, 50 μg). Control MDBK cell extract (AP) was treated with E. coli
alkaline phosphatase (Wartington; 4 U/200 μl of cell lysate) and then with anti-TrpRS antibodies. Postmitochondrial extracts from control
(C) and tryptamine-treated (TN) MDBK cells obtained by homogenization (Dounce glass/glass homogenizer) in 0.25 M sucrose, 0.01 M
Tris-HCl pH 7.5, 1 mM EDTA, and 3 mM DFP after 5 hours of labeling. Extracts (150 μl, 1.5 × 107 cpm) were incubated with mono-
specific anti-TrpRS antibodies (15 μg) for 3 hours at 25°C (B). TrpRS was not detectably phosphorylated in postmitochondrial fraction
of control cells. (C) For TrpRS-catalyzed tryptophan-dependent ATP-PPi exchange, cells were extracted in 0.1% Triton X-100, 50 mM
NaCl, 2 mM MgCl2, 10 mM 2-ME, 50 mM Tris-HCl pH 7.5, and 2 mM DFP for 30 minutes at 0°C. To remove endogenous tryptophan,
detergent-soluble fractions (500 μl) were dialyzed against 2 L (two changes) of buffer (50 mM NaCl, 10 mM 2-ME, 10 mM Tris-HCl
pH 7.5) for 24 hours at 4°C. Protein concentration was measured in extracts using Bradford reagent. Enzymatic reaction (200 μl) in
the presence of Tris-HCl pH 7.5, Mg2+, 0.2% dialyzed gelatin, ATP, PPi, and [
32P]PPi was conducted (37°C) as described previously
[20]. Concentrations of tryptophan (0-1 μM) and cell extracts (25-50 μg/10-20 μl) and incubation time (3-30 min) varied for the reaction
optimization. Immunoprecipitation of detergent-soluble (1% NP-40) fractions with anti-TrpRS IgG was performed after 2.5 hours of
labeling (35S and 32P). Each of these experiments was repeated at least three times, and representative results are shown.
Figure W6. Molecular structures of TrpRS inhibitors, tryptophana-
mide, tryptamine, and tryptophanol.
Table W7. TrpRS Catalyzed Tryptophan-Dependent ATP-[32P]PPi Exchange in Postmitochondrial
Human Tissue Extracts.
Human Tissue Extract Tryptophan-Dependent ATP-[32P]PPi Exchange (cpm)
Placenta 940
Liver (hepatitis) 810
Uterine cancer 175
OVC I 2710
OVC II 1860
Shown are representative results from an experiment that was repeated at least three times. Counts
(cpm) for control probes incubated without tryptophan were deducted.
